Pre-Test Management of Recurrent C. difficile Infection in Patients with IBD: Updates in An Era of Live Biotherapeutic Products Pre-Test Compared to patients without IBD, patients with IBD are _____ more likely to experience CDI recurrence. 23% 33% 43% 53% Unsure Overlapping symptoms can complicate rCDI diagnosis among patients with IBD. Which of the following is a recommended initial test to increase the accuracy of a diagnosis of active CDI? Enzyme immunoassay testing Nucleic acid amplification testing (NAAT) Polymerase chain reaction testing (PCR) Serum antibody testing Unsure Data from the PUNCH CD3 trial demonstrated that treatment with fecal microbiota, live-jslm (previously RBX2660), resulted in a ____ success rate compared to placebo. 50.7% 60.4% 70.6% 80.4% Unsure Data from the ESCOPOR IV phase 3 open-label study demonstrated that only 8.7% of patients treated with ______ experienced recurrence up to 8 weeks. Bezlotoxumab Fecal microbiota spores live-brpk (previously SER-109) RBX2660 Vancomycin Unsure How confident are you in your ability to utilize novel live biotherapeutic products (LBPs) for rCDI treatment among IBD patients when appropriate? Very confident Confident Somewhat confident Not very confident Not at all confident
